Tebentafusp linked with improved survival in patients with metastatic uveal melanoma
- Posted on: Apr 13 2022
- Leave a response
Patients with metastatic uveal melanoma who received tebentafusp had significantly higher 1-year survival rates than patients who received pembrolizumab, ipilimumab, or dacarbazine.
Source: AAO
Posted in: Uncategorized
